Second-Line Combination Chemotherapy with Docetaxel for Cisplatin-Pretreated Refractory Metastatic Esophageal Cancer: A Preliminary Report of Initial Experience

Publisher： Karger

E-ISSN： 1421-9794|53|6|449-453

ISSN： 0009-3157

Source： Chemotherapy, Vol.53, Iss.6, 2007-10, pp. : 449-453

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Combination Chemotherapy with Irinotecan and Ifosfamide as Second-Line Treatment of Refractory or Sensitive Relapsed Small Cell Lung Cancer: A Phase II Study

By  

Chemotherapy, Vol. 49, Iss. 4, 2003-07 ,pp. : 200-205

Karger

Access to resources Recommend Favorite

Efficacy of Docetaxel as a Second-Line Chemotherapy for Thymic Carcinoma

By  

Chemotherapy, Vol. 50, Iss. 6, 2004-12 ,pp. : 279-282

Karger

Access to resources Recommend Favorite

A Retrospective Study of Gemcitabine and Cisplatin Combination Therapy as Second-Line Treatment for Advanced Biliary Tract Cancer

By  

Chemotherapy, Vol. 59, Iss. 2, 2013-09 ,pp. : 106-111

Karger

Access to resources Recommend Favorite

Phase I/II Trial of Irinotecan and S-1 Combination Chemotherapy as a Second-Line Treatment for Advanced Colorectal Cancer

By  

Chemotherapy, Vol. 59, Iss. 5, 2014-05 ,pp. : 338-343

Karger

Access to resources Recommend Favorite

Second-Line Combination Chemotherapy with Vinorelbine and Capecitabine in Patients with Advanced Breast Cancer Previously Treated with Anthracyclines and/or Taxanes

By  

Chemotherapy, Vol. 57, Iss. 1, 2011-02 ,pp. : 71-76

Karger

Access to resources Recommend Favorite